Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response (Q36216264)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

serum concentration

1 reference

based on heuristic

inferred from title

Michael A Fridrik

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Markus Alexander Zeitlinger

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Christine Mannhalter

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Ulrich Jäger

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Daniel Heintel

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Georg Hopfinger

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sonja Burgstaller

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Wilhelm Oberaigner

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Edit Porpaczy

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Cathrin Skrabs

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Christine Einberger

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Johannes Drach

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Markus Raderer

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Alexander Gaiger

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Monique Putman

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Richard Greil

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

17 April 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

97

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1431-1438

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Prognostic tools in follicular lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Diversity in antibody-based approaches to non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Pharmacokinetic properties of rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Pharmacokinetics of rituximab and its clinical use: thought for the best use?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

1 October 2017

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

29 June 2018

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

29 June 2018

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

29 June 2018

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

22 September 2018

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

22 September 2018

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

22 September 2018

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

22 September 2018

Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

22 September 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3436246

22 September 2018

Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22511498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22511498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/22511498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22511498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic Behavior of Rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22511498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/22511498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2011.059246

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22511498%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36216264&oldid=2164858733"